AU2008220449A1 - Methods for distingushing between lung squamous carcinoma and other non smallcell lung cancers - Google Patents

Methods for distingushing between lung squamous carcinoma and other non smallcell lung cancers Download PDF

Info

Publication number: AU2008220449A1
Authority: AU; Australia
Prior art keywords: nucleic acid; sequence; lung; mirna; seq
Prior art date: 2007-03-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2008220449A

Other languages

English (en)

Inventor

Ranit Aharonov

Hila Benjamin

Nitzan Rosenfeld

Shai Rosenwald

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Rosetta Genomics Ltd

Original Assignee

Rosetta Genomics Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-03-01

Filing date

2008-02-28

Publication date

2008-09-04

2008-02-28 Application filed by Rosetta Genomics Ltd filed Critical Rosetta Genomics Ltd

2008-09-04 Publication of AU2008220449A1 publication Critical patent/AU2008220449A1/en

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims description 67
210000004072 lung Anatomy 0.000 title claims description 28
208000002154 non-small cell lung carcinoma Diseases 0.000 title claims description 24
206010041823 squamous cell carcinoma Diseases 0.000 title claims description 16
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 title 1
239000000523 sample Substances 0.000 claims description 141
150000007523 nucleic acids Chemical group 0.000 claims description 123
102000039446 nucleic acids Human genes 0.000 claims description 102
108020004707 nucleic acids Proteins 0.000 claims description 102
230000014509 gene expression Effects 0.000 claims description 61
208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 23
201000005249 lung adenocarcinoma Diseases 0.000 claims description 23
108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 20
239000012472 biological sample Substances 0.000 claims description 17
238000003753 real-time PCR Methods 0.000 claims description 14
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 12
208000003849 large cell carcinoma Diseases 0.000 claims description 12
230000002441 reversible effect Effects 0.000 claims description 12
238000000018 DNA microarray Methods 0.000 claims description 11
239000012634 fragment Substances 0.000 claims description 10
238000007901 in situ hybridization Methods 0.000 claims description 10
238000004458 analytical method Methods 0.000 claims description 8
238000003199 nucleic acid amplification method Methods 0.000 claims description 7
230000003321 amplification Effects 0.000 claims description 6
239000003153 chemical reaction reagent Substances 0.000 claims description 6
201000009546 lung large cell carcinoma Diseases 0.000 claims description 6
238000007899 nucleic acid hybridization Methods 0.000 claims description 5
210000001124 body fluid Anatomy 0.000 claims description 2
238000005259 measurement Methods 0.000 claims description 2
239000007790 solid phase Substances 0.000 claims description 2
239000002679 microRNA Substances 0.000 description 147
108700011259 MicroRNAs Proteins 0.000 description 101
125000003729 nucleotide group Chemical group 0.000 description 70
239000002773 nucleotide Substances 0.000 description 64
210000004027 cell Anatomy 0.000 description 62
108091032973 (ribonucleotides)n+m Proteins 0.000 description 43
230000000295 complement effect Effects 0.000 description 40
108090000623 proteins and genes Proteins 0.000 description 32
210000001519 tissue Anatomy 0.000 description 31
238000009396 hybridization Methods 0.000 description 26
238000009739 binding Methods 0.000 description 25
239000000203 mixture Substances 0.000 description 24
108091007428 primary miRNA Proteins 0.000 description 20
239000013598 vector Substances 0.000 description 20
238000001514 detection method Methods 0.000 description 19
108091070501 miRNA Proteins 0.000 description 19
108091067482 Homo sapiens miR-205 stem-loop Proteins 0.000 description 17
208000009956 adenocarcinoma Diseases 0.000 description 16
206010028980 Neoplasm Diseases 0.000 description 15
238000010839 reverse transcription Methods 0.000 description 14
108700005078 Synthetic Genes Proteins 0.000 description 12
239000000872 buffer Substances 0.000 description 12
238000003745 diagnosis Methods 0.000 description 12
108020004999 messenger RNA Proteins 0.000 description 12
239000000243 solution Substances 0.000 description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
238000003556 assay Methods 0.000 description 10
201000011510 cancer Diseases 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
208000020816 lung neoplasm Diseases 0.000 description 9
239000007787 solid Substances 0.000 description 9
239000000758 substrate Substances 0.000 description 9
241001465754 Metazoa Species 0.000 description 8
102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 8
108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 8
239000011230 binding agent Substances 0.000 description 8
239000002299 complementary DNA Substances 0.000 description 8
108020004414 DNA Proteins 0.000 description 7
238000011529 RT qPCR Methods 0.000 description 7
238000003776 cleavage reaction Methods 0.000 description 7
238000011534 incubation Methods 0.000 description 7
238000002372 labelling Methods 0.000 description 7
230000004048 modification Effects 0.000 description 7
238000012986 modification Methods 0.000 description 7
-1 rRNA Proteins 0.000 description 7
230000001105 regulatory effect Effects 0.000 description 7
230000007017 scission Effects 0.000 description 7
230000035945 sensitivity Effects 0.000 description 7
238000012360 testing method Methods 0.000 description 7
229910021642 ultra pure water Inorganic materials 0.000 description 7
239000012498 ultrapure water Substances 0.000 description 7
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
108091026890 Coding region Proteins 0.000 description 6
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
238000005406 washing Methods 0.000 description 6
SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 5
108091070493 Homo sapiens miR-21 stem-loop Proteins 0.000 description 5
108091008065 MIR21 Proteins 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
230000000692 anti-sense effect Effects 0.000 description 5
230000004663 cell proliferation Effects 0.000 description 5
QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 5
SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 5
235000019441 ethanol Nutrition 0.000 description 5
239000013604 expression vector Substances 0.000 description 5
239000003550 marker Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
238000004393 prognosis Methods 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
230000028327 secretion Effects 0.000 description 5
239000000126 substance Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
201000009030 Carcinoma Diseases 0.000 description 4
102000016911 Deoxyribonucleases Human genes 0.000 description 4
108010053770 Deoxyribonucleases Proteins 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
108010090804 Streptavidin Proteins 0.000 description 4
238000000692 Student's t-test Methods 0.000 description 4
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
230000001594 aberrant effect Effects 0.000 description 4
238000000137 annealing Methods 0.000 description 4
238000003491 array Methods 0.000 description 4
238000001574 biopsy Methods 0.000 description 4
238000009826 distribution Methods 0.000 description 4
125000000524 functional group Chemical group 0.000 description 4
239000011521 glass Substances 0.000 description 4
230000003993 interaction Effects 0.000 description 4
239000013642 negative control Substances 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
239000002243 precursor Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
125000002652 ribonucleotide group Chemical group 0.000 description 4
238000007619 statistical method Methods 0.000 description 4
238000012353 t test Methods 0.000 description 4
230000002103 transcriptional effect Effects 0.000 description 4
238000013519 translation Methods 0.000 description 4
238000011282 treatment Methods 0.000 description 4
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
108010067770 Endopeptidase K Proteins 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
206010058467 Lung neoplasm malignant Diseases 0.000 description 3
108091030146 MiRBase Proteins 0.000 description 3
208000005927 Myosarcoma Diseases 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
102000003661 Ribonuclease III Human genes 0.000 description 3
108010057163 Ribonuclease III Proteins 0.000 description 3
239000006180 TBST buffer Substances 0.000 description 3
108020004566 Transfer RNA Proteins 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
238000004422 calculation algorithm Methods 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000000975 dye Substances 0.000 description 3
238000000605 extraction Methods 0.000 description 3
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
201000005202 lung cancer Diseases 0.000 description 3
238000002493 microarray Methods 0.000 description 3
201000002077 muscle cancer Diseases 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
239000004033 plastic Substances 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
230000008569 process Effects 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
238000012545 processing Methods 0.000 description 3
230000010076 replication Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
206010001233 Adenoma benign Diseases 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
201000003076 Angiosarcoma Diseases 0.000 description 2
108091032955 Bacterial small RNA Proteins 0.000 description 2
201000000274 Carcinosarcoma Diseases 0.000 description 2
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
208000005243 Chondrosarcoma Diseases 0.000 description 2
241000699802 Cricetulus griseus Species 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
241000701832 Enterobacteria phage T3 Species 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
201000008808 Fibrosarcoma Diseases 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
208000001258 Hemangiosarcoma Diseases 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
108091062154 Mir-205 Proteins 0.000 description 2
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
206010061332 Paraganglion neoplasm Diseases 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
206010036790 Productive cough Diseases 0.000 description 2
101710086015 RNA ligase Proteins 0.000 description 2
108091028664 Ribonucleotide Proteins 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
108020004459 Small interfering RNA Proteins 0.000 description 2
FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
230000021736 acetylation Effects 0.000 description 2
238000006640 acetylation reaction Methods 0.000 description 2
230000004913 activation Effects 0.000 description 2
150000003838 adenosines Chemical class 0.000 description 2
150000001413 amino acids Chemical group 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
239000000090 biomarker Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
238000009835 boiling Methods 0.000 description 2
238000006664 bond formation reaction Methods 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000006260 foam Substances 0.000 description 2
230000002538 fungal effect Effects 0.000 description 2
239000005090 green fluorescent protein Substances 0.000 description 2
125000001475 halogen functional group Chemical group 0.000 description 2
210000003630 histaminocyte Anatomy 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
206010024627 liposarcoma Diseases 0.000 description 2
208000012804 lymphangiosarcoma Diseases 0.000 description 2
230000000527 lymphocytic effect Effects 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
108091023127 miR-196 stem-loop Proteins 0.000 description 2
238000001531 micro-dissection Methods 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
208000001611 myxosarcoma Diseases 0.000 description 2
IDBIFFKSXLYUOT-UHFFFAOYSA-N netropsin Chemical compound C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)CN=C(N)N)=CN1C IDBIFFKSXLYUOT-UHFFFAOYSA-N 0.000 description 2
208000007312 paraganglioma Diseases 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
238000010188 recombinant method Methods 0.000 description 2
201000009410 rhabdomyosarcoma Diseases 0.000 description 2
239000002336 ribonucleotide Substances 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000002924 silencing RNA Substances 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
239000004055 small Interfering RNA Substances 0.000 description 2
229910001415 sodium ion Inorganic materials 0.000 description 2
210000003802 sputum Anatomy 0.000 description 2
208000024794 sputum Diseases 0.000 description 2
238000010186 staining Methods 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000002123 temporal effect Effects 0.000 description 2
229940113082 thymine Drugs 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
229940035893 uracil Drugs 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
239000008096 xylene Substances 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
CALDMMCNNFPJSI-CRCLSJGQSA-N (3r,5s)-5-(hydroxymethyl)pyrrolidin-3-ol Chemical compound OC[C@@H]1C[C@@H](O)CN1 CALDMMCNNFPJSI-CRCLSJGQSA-N 0.000 description 1
RLMLFADXHJLPSQ-NPPFTVEMSA-N (3s,6s,9s,12s,15s,18s,21s,24r,27s)-3,6-dibenzyl-12,24-bis[(2r)-butan-2-yl]-15-(2-hydroxypropan-2-yl)-4,10,16,22-tetramethyl-18-(2-methylpropyl)-9,21-di(propan-2-yl)-13-oxa-1,4,7,10,16,19,22,25-octazabicyclo[25.3.0]triacontane-2,5,8,11,14,17,20,23,26-nonon Chemical compound C([C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(N(C)[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N(C)[C@H](C(=O)O[C@H](C(=O)N(C)[C@@H](C(C)C)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N1C)[C@H](C)CC)C(C)(C)O)=O)[C@H](C)CC)C1=CC=CC=C1 RLMLFADXHJLPSQ-NPPFTVEMSA-N 0.000 description 1
QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
GZEFTKHSACGIBG-UGKPPGOTSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-propyloxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1=CC(=O)NC(=O)N1[C@]1(CCC)O[C@H](CO)[C@@H](O)[C@H]1O GZEFTKHSACGIBG-UGKPPGOTSA-N 0.000 description 1
101150072531 10 gene Proteins 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 1
108020005345 3' Untranslated Regions Proteins 0.000 description 1
108020003589 5' Untranslated Regions Proteins 0.000 description 1
QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
108020004565 5.8S Ribosomal RNA Proteins 0.000 description 1
108020005075 5S Ribosomal RNA Proteins 0.000 description 1
ASUCSHXLTWZYBA-UMMCILCDSA-N 8-Bromoguanosine Chemical compound C1=2NC(N)=NC(=O)C=2N=C(Br)N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ASUCSHXLTWZYBA-UMMCILCDSA-N 0.000 description 1
HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
208000010400 APUDoma Diseases 0.000 description 1
208000007876 Acrospiroma Diseases 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
208000000583 Adenolymphoma Diseases 0.000 description 1
208000003200 Adenoma Diseases 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
208000005034 Angiolymphoid Hyperplasia with Eosinophilia Diseases 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
108091023037 Aptamer Proteins 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000035821 Benign schwannoma Diseases 0.000 description 1
208000003609 Bile Duct Adenoma Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
208000000529 Branchioma Diseases 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
206010007270 Carcinoid syndrome Diseases 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
208000007389 Cementoma Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
206010008263 Cervical dysplasia Diseases 0.000 description 1
206010008642 Cholesteatoma Diseases 0.000 description 1
201000005262 Chondroma Diseases 0.000 description 1
201000009047 Chordoma Diseases 0.000 description 1
208000016216 Choristoma Diseases 0.000 description 1
208000009798 Craniopharyngioma Diseases 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
201000005171 Cystadenoma Diseases 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
102100024746 Dihydrofolate reductase Human genes 0.000 description 1
102100021210 Double homeobox protein B Human genes 0.000 description 1
208000007033 Dysgerminoma Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
206010063045 Effusion Diseases 0.000 description 1
208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
206010014967 Ependymoma Diseases 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
208000006168 Ewing Sarcoma Diseases 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
206010053717 Fibrous histiocytoma Diseases 0.000 description 1
108700023863 Gene Components Proteins 0.000 description 1
208000007569 Giant Cell Tumors Diseases 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
201000005618 Glomus Tumor Diseases 0.000 description 1
108010060309 Glucuronidase Proteins 0.000 description 1
102000053187 Glucuronidase Human genes 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
208000005234 Granulosa Cell Tumor Diseases 0.000 description 1
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
208000035773 Gynandroblastoma Diseases 0.000 description 1
208000002927 Hamartoma Diseases 0.000 description 1
208000002125 Hemangioendothelioma Diseases 0.000 description 1
208000006050 Hemangiopericytoma Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101000968521 Homo sapiens Double homeobox protein B Proteins 0.000 description 1
101000574648 Homo sapiens Retinoid-inducible serine carboxypeptidase Proteins 0.000 description 1
108091069017 Homo sapiens miR-140 stem-loop Proteins 0.000 description 1
108091067605 Homo sapiens miR-183 stem-loop Proteins 0.000 description 1
108091092296 Homo sapiens miR-202 stem-loop Proteins 0.000 description 1
108091092304 Homo sapiens miR-492 stem-loop Proteins 0.000 description 1
108091064471 Homo sapiens miR-525 stem-loop Proteins 0.000 description 1
241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
208000009164 Islet Cell Adenoma Diseases 0.000 description 1
108010025815 Kanamycin Kinase Proteins 0.000 description 1
208000018142 Leiomyosarcoma Diseases 0.000 description 1
201000004462 Leydig Cell Tumor Diseases 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
206010024612 Lipoma Diseases 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
206010025219 Lymphangioma Diseases 0.000 description 1
208000004138 Lymphangiomyoma Diseases 0.000 description 1
208000008095 Malignant Carcinoid Syndrome Diseases 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
208000010153 Mesonephroma Diseases 0.000 description 1
206010027406 Mesothelioma Diseases 0.000 description 1
208000007727 Muscle Tissue Neoplasms Diseases 0.000 description 1
VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 description 1
VQAYFKKCNSOZKM-UHFFFAOYSA-N NSC 29409 Natural products C1=NC=2C(NC)=NC=NC=2N1C1OC(CO)C(O)C1O VQAYFKKCNSOZKM-UHFFFAOYSA-N 0.000 description 1
206010061309 Neoplasm progression Diseases 0.000 description 1
108010042309 Netropsin Proteins 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
201000004404 Neurofibroma Diseases 0.000 description 1
208000009905 Neurofibromatoses Diseases 0.000 description 1
208000005890 Neuroma Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
241001440127 Phyllodes Species 0.000 description 1
208000007641 Pinealoma Diseases 0.000 description 1
108091007412 Piwi-interacting RNA Proteins 0.000 description 1
208000007452 Plasmacytoma Diseases 0.000 description 1
102000015623 Polynucleotide Adenylyltransferase Human genes 0.000 description 1
108010024055 Polynucleotide adenylyltransferase Proteins 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
238000002123 RNA extraction Methods 0.000 description 1
239000013614 RNA sample Substances 0.000 description 1
208000034541 Rare lymphatic malformation Diseases 0.000 description 1
206010038802 Reticuloendothelial system stimulated Diseases 0.000 description 1
102100025483 Retinoid-inducible serine carboxypeptidase Human genes 0.000 description 1
208000005678 Rhabdomyoma Diseases 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
102000004389 Ribonucleoproteins Human genes 0.000 description 1
108010081734 Ribonucleoproteins Proteins 0.000 description 1
108091006629 SLC13A2 Proteins 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
208000003274 Sertoli cell tumor Diseases 0.000 description 1
208000002669 Sex Cord-Gonadal Stromal Tumors Diseases 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
102000039471 Small Nuclear RNA Human genes 0.000 description 1
108091027967 Small hairpin RNA Proteins 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
206010042658 Sweat gland tumour Diseases 0.000 description 1
206010043276 Teratoma Diseases 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
208000021146 Warthin tumor Diseases 0.000 description 1
108010084455 Zeocin Proteins 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
229920006397 acrylic thermoplastic Polymers 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
201000004471 adenofibroma Diseases 0.000 description 1
208000018234 adnexal spiradenoma/cylindroma of a sweat gland Diseases 0.000 description 1
238000007605 air drying Methods 0.000 description 1
PPQRONHOSHZGFQ-LMVFSUKVSA-N aldehydo-D-ribose 5-phosphate Chemical group OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PPQRONHOSHZGFQ-LMVFSUKVSA-N 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
208000010029 ameloblastoma Diseases 0.000 description 1
201000009431 angiokeratoma Diseases 0.000 description 1
208000000252 angiomatosis Diseases 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
210000001106 artificial yeast chromosome Anatomy 0.000 description 1
210000003567 ascitic fluid Anatomy 0.000 description 1
108010008887 aureobasidin A Proteins 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
229940120638 avastin Drugs 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
210000000270 basal cell Anatomy 0.000 description 1
208000021592 benign granular cell tumor Diseases 0.000 description 1
229960000397 bevacizumab Drugs 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000004791 biological behavior Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
230000005773 cancer-related death Effects 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
208000005761 carcinoid heart disease Diseases 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000032823 cell division Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000003320 cell separation method Methods 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
230000007960 cellular response to stress Effects 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
210000003756 cervix mucus Anatomy 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
201000005217 chondroblastoma Diseases 0.000 description 1
ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
230000002079 cooperative effect Effects 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
208000002445 cystadenocarcinoma Diseases 0.000 description 1
230000002559 cytogenic effect Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
238000013480 data collection Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000000368 destabilizing effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
108020001096 dihydrofolate reductase Proteins 0.000 description 1
XNYZHCFCZNMTFY-UHFFFAOYSA-N diminazene Chemical compound C1=CC(C(=N)N)=CC=C1N\N=N\C1=CC=C(C(N)=N)C=C1 XNYZHCFCZNMTFY-UHFFFAOYSA-N 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002121 endocytic effect Effects 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
206010016629 fibroma Diseases 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
230000005021 gait Effects 0.000 description 1
201000008361 ganglioneuroma Diseases 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
230000009368 gene silencing by RNA Effects 0.000 description 1
230000037440 gene silencing effect Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
201000005626 glomangioma Diseases 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
229940096919 glycogen Drugs 0.000 description 1
230000012010 growth Effects 0.000 description 1
210000004209 hair Anatomy 0.000 description 1
201000011066 hemangioma Diseases 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
201000005133 hidradenoma Diseases 0.000 description 1
201000009379 histiocytoid hemangioma Diseases 0.000 description 1
201000000284 histiocytoma Diseases 0.000 description 1
201000008298 histiocytosis Diseases 0.000 description 1
230000003118 histopathologic effect Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
201000002529 islet cell tumor Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
201000010260 leiomyoma Diseases 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
201000008443 lung non-squamous non-small cell carcinoma Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
206010027191 meningioma Diseases 0.000 description 1
208000004197 mesenchymoma Diseases 0.000 description 1
208000011831 mesonephric neoplasm Diseases 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
AYYOZKHMSABVRP-UHFFFAOYSA-N methyl 1h-indole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C=CNC2=C1 AYYOZKHMSABVRP-UHFFFAOYSA-N 0.000 description 1
108091043720 miR-513 stem-loop Proteins 0.000 description 1
108091007426 microRNA precursor Proteins 0.000 description 1
238000001000 micrograph Methods 0.000 description 1
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
201000004130 myoblastoma Diseases 0.000 description 1
208000009091 myxoma Diseases 0.000 description 1
UPBAOYRENQEPJO-UHFFFAOYSA-N n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-formamido-1-methylpyrrole-2-carboxamide Chemical compound CN1C=C(NC=O)C=C1C(=O)NC1=CN(C)C(C(=O)NC2=CN(C)C(C(=O)NCCC(N)=N)=C2)=C1 UPBAOYRENQEPJO-UHFFFAOYSA-N 0.000 description 1
208000007538 neurilemmoma Diseases 0.000 description 1
208000029986 neuroepithelioma Diseases 0.000 description 1
201000004931 neurofibromatosis Diseases 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
108091027963 non-coding RNA Proteins 0.000 description 1
102000042567 non-coding RNA Human genes 0.000 description 1
238000010606 normalization Methods 0.000 description 1
238000003499 nucleic acid array Methods 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
210000004287 null lymphocyte Anatomy 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
208000004128 odontoma Diseases 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
208000008798 osteoma Diseases 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
125000004043 oxo group Chemical group O=* 0.000 description 1
208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
208000003154 papilloma Diseases 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
229960004448 pentamidine Drugs 0.000 description 1
239000012071 phase Substances 0.000 description 1
CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
238000000206 photolithography Methods 0.000 description 1
230000009894 physiological stress Effects 0.000 description 1
INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
208000024724 pineal body neoplasm Diseases 0.000 description 1
201000004123 pineal gland cancer Diseases 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229960003171 plicamycin Drugs 0.000 description 1
229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920001748 polybutylene Polymers 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
238000011002 quantification Methods 0.000 description 1
UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 description 1
102000005912 ran GTP Binding Protein Human genes 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
150000003290 ribose derivatives Chemical group 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
206010039667 schwannoma Diseases 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
150000003376 silicon Chemical class 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
108091029842 small nuclear ribonucleic acid Proteins 0.000 description 1
241000894007 species Species 0.000 description 1
239000012192 staining solution Substances 0.000 description 1
108010042747 stallimycin Proteins 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000013179 statistical model Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
206010042863 synovial sarcoma Diseases 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
210000001138 tear Anatomy 0.000 description 1
ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
208000001644 thecoma Diseases 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
208000008732 thymoma Diseases 0.000 description 1
238000012549 training Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000009752 translational inhibition Effects 0.000 description 1
239000003656 tris buffered saline Substances 0.000 description 1
208000029387 trophoblastic neoplasm Diseases 0.000 description 1
HDZZVAMISRMYHH-KCGFPETGSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HDZZVAMISRMYHH-KCGFPETGSA-N 0.000 description 1
239000000439 tumor marker Substances 0.000 description 1
230000005751 tumor progression Effects 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Immunology (AREA)
Analytical Chemistry (AREA)
Genetics & Genomics (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Pathology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

AU2008220449A 2007-03-01 2008-02-28 Methods for distingushing between lung squamous carcinoma and other non smallcell lung cancers Abandoned AU2008220449A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US90417107P	2007-03-01	2007-03-01
US60/904,171		2007-03-01
US2134608P	2008-01-16	2008-01-16
US61/021,346		2008-01-16
PCT/IL2008/000261 WO2008104985A2 (fr)	2007-03-01	2008-02-28	Procédés pour distinguer un carcinome squameux du poumon d'autres cancers du poumon à non-petites cellules

Publications (1)

Publication Number	Publication Date
AU2008220449A1 true AU2008220449A1 (en)	2008-09-04

Family

ID=39616499

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2008220449A Abandoned AU2008220449A1 (en)	2007-03-01	2008-02-28	Methods for distingushing between lung squamous carcinoma and other non smallcell lung cancers

Country Status (5)

Country	Link
EP (1)	EP2126116A2 (fr)
JP (1)	JP2010519899A (fr)
AU (1)	AU2008220449A1 (fr)
CA (1)	CA2677043A1 (fr)
WO (1)	WO2008104985A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010070637A2 (fr) *	2008-12-15	2010-06-24	Rosetta Genomics Ltd.	Procédé permettant de distinguer les tumeurs des surrénales entre elles
CN101475984A (zh) *	2008-12-15	2009-07-08	江苏命码生物科技有限公司	一种非小细胞肺癌检测标记物及其检测方法、相关生物芯片和试剂盒
WO2010103522A1 (fr) *	2009-03-10	2010-09-16	Rosetta Genomics Ltd.	Procédé de détection de séquences d'acide nucléique
EP2419538B1 (fr) *	2009-04-16	2016-09-14	Padma Arunachalam	Procédés et compositions visant à détecter et à différencier de petits arn dans un chemin de maturation d'arn
WO2012131670A2 (fr)	2011-03-28	2012-10-04	Rosetta Genomics Ltd	Procédés pour la classification des cancers du poumon
EP3468605A4 (fr)	2016-06-08	2020-01-08	President and Fellows of Harvard College	Vecteur viral modifié réduisant l'induction de réponses inflammatoires et immunitaires
AU2018364542A1 (en)	2017-11-08	2020-04-16	President And Fellows Of Harvard College	Compositions and methods for inhibiting viral vector-induced inflammatory responses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2554818A1 (fr) *	2004-02-09	2005-08-25	Thomas Jefferson University	Diagnostic et traitement de cancers a l'aide de microarn present dans ou au voisinage de caracteristiques chromosomiennes liees aux cancers
WO2007148235A2 (fr) *	2006-05-04	2007-12-27	Rosetta Genomics Ltd	Acides nucléiques apparentés au cancer

2008
- 2008-02-28 EP EP08710261A patent/EP2126116A2/fr not_active Withdrawn
- 2008-02-28 AU AU2008220449A patent/AU2008220449A1/en not_active Abandoned
- 2008-02-28 CA CA002677043A patent/CA2677043A1/fr not_active Abandoned
- 2008-02-28 WO PCT/IL2008/000261 patent/WO2008104985A2/fr not_active Ceased
- 2008-02-28 JP JP2009551310A patent/JP2010519899A/ja active Pending

Also Published As

Publication number	Publication date
CA2677043A1 (fr)	2008-09-04
EP2126116A2 (fr)	2009-12-02
WO2008104985A2 (fr)	2008-09-04
JP2010519899A (ja)	2010-06-10
WO2008104985A3 (fr)	2008-11-06

Publication	Publication Date	Title
US9133522B2 (en)	2015-09-15	Compositions and methods for the diagnosis and prognosis of mesothelioma
US20150099665A1 (en)	2015-04-09	Methods for distinguishing between specific types of lung cancers
WO2010018563A2 (fr)	2010-02-18	Compositions et procédés de pronostic d'un lymphome
WO2007148235A2 (fr)	2007-12-27	Acides nucléiques apparentés au cancer
US20100273172A1 (en)	2010-10-28	Micrornas expression signature for determination of tumors origin
EP2691545B1 (fr)	2017-06-14	Procédés pour la classification des cancers du poumon
EP2643479A2 (fr)	2013-10-02	Procédés et matériaux pour la classification de tissus originaires d'échantillons tumoraux
AU2008220449A1 (en)	2008-09-04	Methods for distingushing between lung squamous carcinoma and other non smallcell lung cancers
US9068232B2 (en)	2015-06-30	Gene expression signature for classification of kidney tumors
US9834821B2 (en)	2017-12-05	Diagnosis and prognosis of various types of cancers
WO2011024157A1 (fr)	2011-03-03	Séquences d'acides nucléiques liées au cancer
WO2010004562A2 (fr)	2010-01-14	Procédés et compositions permettant de détecter un cancer colorectal
WO2011030334A1 (fr)	2011-03-17	Compositions et procédés pour le traitement, le diagnostic et le pronostic de mésothéliome
WO2009066291A2 (fr)	2009-05-28	Signature d'expression de micro-arn pour la détermination de l'origine de tumeurs
US20130123138A1 (en)	2013-05-16	Compositions and methods for prognosis of mesothelioma
US8563252B2 (en)	2013-10-22	Methods for distinguishing between lung squamous carcinoma and other non small cell lung cancers
WO2010058393A2 (fr)	2010-05-27	Compositions et procédés pour le pronostic du cancer du côlon
WO2010070637A2 (fr)	2010-06-24	Procédé permettant de distinguer les tumeurs des surrénales entre elles
WO2011039757A2 (fr)	2011-04-07	Compositions et méthodes de pronostic du cancer du rein
WO2010016064A2 (fr)	2010-02-11	Signature d'expression génique pour la classification de tumeurs de rein

Legal Events

Date	Code	Title	Description
2009-09-10	DA3	Amendments made section 104	Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ METHODS FOR DISTINGUSHING BETWEENLUNG SQUAMOUS CARCINOMA AND OTHER NON SMALLCELL LUNG CANCERS
2012-03-01	MK1	Application lapsed section 142(2)(a) - no request for examination in relevant period